Mmr vaccine Health Dictionary

A preparation of dead particulate or weakened bacteria or viruses prepared for injection into the body so that antibodies are formed to prevent disease (eg polio). Detoxi fied but genetically potent toxins (called toxoids) can also be used (e.g. tetanus and diphtheria)... vaccine

Often called the TRIPLE VACCINE, the injections produce immunity against DIPHTHERIA, whooping cough (PERTUSSIS) and TETANUS. The vaccine is given as a course of three injections to infants around the ages of two, three and four months, together with haemophilus in?uenza B and meningococcal C vaccine as well as oral polio vaccine. A booster injection is given at school entry (see schedule in IMMUNISATION).... dpt vaccine

A vaccine obtained by treating the POLIOMYELITIS virus with formalin. This prevents the virus from causing the disease but allows it to stimulate the production of ANTIBODIES. Salk vaccine is given by injection and protects the recipient against the disease. (See also IMMUNISATION.)... salk vaccine

A combined VACCINE administered to produce IMMUNITY against typhoid and paratyphoid A and B (see ENTERIC FEVER). (See also IMMUNISATION.)... tab vaccine

Also known as DPT vaccine, this is an injection that provides IMMUNITY against DIPHTHERIA, pertussis (whooping-cough) and TETANUS. It is given as a course of three injections at around the ages of two, three and four months. A booster dose of diphtheria and tetanus is given at primary-school age. Certain infants – those with a family history of EPILEPSY, or who have neurological disorders or who have reacted severely to the ?rst dose – should not have the pertussis element of DPT. (See MMR VACCINE; IMMUNISATION.)... triple vaccine

A vaccine administered routinely at 2, 3, and 4 months of age to provide immunity to the bacterium HAEMOPHILUS INFLUENZA type b (Hib).

Before the vaccine was generally available, Hib infection was a common cause of bacterial meningitis and epiglottitis in children.... hib vaccine

BCG (Bacillus Calmette-Guérin) vaccine, which was ?rst introduced in France in 1908, is the only vaccine that has produced signi?cant immunity against the tubercle bacillus (see TUBERCULOSIS) and at the same time has proved safe enough for use in human subjects. BCG vaccination is usually considered for the following groups of people. (1) Schoolchildren: the routine programme in schools usually covers children aged between ten and 14. (2) Students, including those in teacher training colleges. (3) Immigrants from countries with a high prevalence of tuberculosis (TB). (4) Children and newborn infants born in the UK to parents from Group 3, or other newborns at parents’ request. (5) Health workers, such as nurses, and others likely to be exposed to infection in their work. (6) Veterinary workers who handle animals susceptible to TB. (7) Sta? of prisons, residential homes and hostels for refugees and the homeless. (8) Household contacts of people known to have active TB and newborn infants in households where there is a history of the disease. (9) Those staying for more than one month in high-risk countries.

A pre-vaccination tuberculin test is necessary in all age-groups except newborn infants, and only those with negative tuberculin reactions are vaccinated. Complications are few and far between. A local reaction at the site of vaccination usually occurs between two and six weeks after vaccination, beginning as a small papule that slowly increases in size. It may produce a small ulcer. This heals after around two months, leaving a small scar. (See IMMUNITY; TUBERCULIN.)... bcg vaccine

Introduced in 1962, the attenuated live oral vaccine (Sabin) against POLIOMYELITIS replaced the previous inactivated vaccine introduced in 1956 (see SALK VACCINE).... sabin vaccine

chick embryos injected with the living, attenuated strain (17D) of pantropic virus. Only one injection is required, and immunity persists for many years. Re-inoculation, however, is desirable every ten years. (See YELLOW FEVER.)

Haemophilus vaccine (HiB) This vaccine was introduced in the UK in 1994 to deal with the annual incidence of about 1,500 cases and 100 deaths from haemophilus MENINGITIS, SEPTICAEMIA and EPIGLOTTITIS, mostly in pre-school children. It has been remarkably successful when given as part of the primary vaccination programme at two, three and four months of age – reducing the incidence by over 95 per cent. A few cases still occur, either due to other subgroups of the organism for which the vaccine is not designed, or because of inadequate response by the child, possibly related to interference from the newer forms of pertussis vaccine (see above) given at the same time.

Meningococcal C vaccine Used in the UK from 1998, this has dramatically reduced the incidence of meningitis and septicaemia due to this organism. Used as part of the primary programme in early infancy, it does not protect against other types of meningococci.

Varicella vaccine This vaccine, used to protect against varicella (CHICKENPOX) is used in a number of countries including the United States and Japan. It has not been introduced into the UK, largely because of concerns that use in infancy would result in an upsurge in cases in adult life, when the disease may be more severe.

Pneumococcal vaccine The pneumococcus is responsible for severe and sometimes fatal childhood diseases including meningitis and septicaemia, as well as PNEUMONIA and other respiratory infections. Vaccines are available but do not protect against all strains and are reserved for special situations – such as for patients without a SPLEEN or those who are immunode?cient.... yellow fever vaccine is prepared from

a vaccine that provides protection against four different strains (A, C, W, and Y) of the bacterium Neisseria meningitidis (the meningococcus) that causes *meningitis and septicaemia. It also prevents the carriage of the bacteria in the nose and back of the throat. In Britain it is offered to children aged 14 years and students going to college and university for the first time.... menacwy vaccine

(MenB) a vaccine that provides protection against the B strain of the bacterium Neisseria meningitidis (the meningococcus), which accounts for more than 90% of meningococcal infections in young children. The MenB vaccine is offered to all babies with their primary *immunizations at 2 and 4 months of age and as a booster at 12 months. See meningitis.... meningitis b vaccine

(MenC) a vaccine that provides protection against the C strain of the bacterium Neisseria meningitidis (the meningococcus), which accounts for approximately 50% of all cases of meningococcal meningitis and tends to occur in clusters. Owing to the success of the MenC vaccination programme begun in 1999 there have been almost no recent cases of meningitis C disease in babies and young children in the UK. The vaccine was previously offered to all babies at 12 weeks of age but is now given at 12 months as part of Hib/MenC vaccine and at 14 years as the MenACWY vaccine.... meningitis c vaccine

(in Britain), a vaccine currently offered to all 2- and 3-year-olds in the form of a spray into each nostril. It contains live forms of the influenza virus that have been attenuated (weakened). The vaccine stimulates the immune system but does not cause disease in healthy people.... nasal flu vaccine

a vaccine that protects against infection by the bacterium *Streptococcus pneumoniae, which can cause serious diseases, including pneumonia, septicaemia, and *meningitis. Children under 2 years of age and adults over 65 years are at particular risk. Since September 2006, the pneumococcal vaccine has become part of the childhood *immunization programme. It is also offered to people over the age of 65 as a single vaccination that will protect for life.... pneumococcal vaccine

an oral vaccine against *rotavirus infection. In Britain it is offered to babies at 2 and 3 months of age, alongside their other childhood vaccinations.... rotavirus vaccine

an oral vaccine against (E954) poliomyelitis, prepared by culture of the virus under special conditions so that it loses its virulence (i.e. it becomes attenuated) but retains its ability to stimulate antibody production. [A. B. Sabin (1906–93), US bacteriologist]...  sabin vaccine